Delcath Systems recently announced that it appointed Kevin Muir as VP of commercial operations.
Prior to joining the company, Muir was the director of sales for the embolic interventional oncology business at BTG, which was recently acquired by Boston Scientific.
“We are thrilled that Kevin is joining the Delcath team as VP of commercial operations. He is a seasoned and accomplished leader with experience across multiple innovative medical technologies with a recent focus in the growing field of interventional oncology,” CEO Gerard Michel said in a news release. “Kevin’s proven ability to both build commercial teams and introduce novel technologies into the marketplace will be a critical asset as we prepare for the launch of HEPZATO upon anticipated FDA approval. His hire is another important step in Delcath’s transition from a development to commercial stage company.”
Muir has more than 20 years of sales and marketing experience in biotherapeutics and medical technology. He has served as the director of U.S. sales for interventional oncology at BTG, director of sales at ClearFlow and Aragon Surgical and has held numerous leadership roles at Kensey Nash Corporation, Kyphon and Genzyme Biosurgery.
“Delcath’s Hepzato platform has the potential to make a substantial difference in the lives of the many patients who are suffering from primary or metastatic cancers of the liver. I am joining at an exciting time, with the announcement of topline data from the pivotal FOCUS trial anticipated in early 2021, followed by an expected NDA resubmission and launch in the U.S. in 2022 for the treatment of patients with hepatic dominant metastatic ocular melanoma. I look forward to leading the prelaunch planning and eventual commercialization of Hepzato, as well as working with the broader team as we expand the platform to treat other tumor types upon execution of further clinical investigations,” Muir said.
Delcath’s Hepzato kit is designed to administer high-dose chemotherapy to the liver, while controlling systemic exposure and associated side effects, according to the company.